Auradine Unveils AuraLinks™ to Transform GenAI Data Center Network FabricsAuradine Unveils AuraLinks™ to Transform GenAI Data Center Network Fabrics GlobeNewswire
||
Auradine has joined the Ultra Accelerator Link (UAL) and Ultra Ethernet Link consortiums as a member and contributor for open standards for scale-up and scale-out AI networking.AuraLinks fabrics are... 
Neurophet to Participate in RSNA 2024: Unveiling Multiple Sclerosis Analysis Technology with Neurophet AQUANeurophet to Participate in RSNA 2024: Unveiling Multiple Sclerosis Analysis Technology with Neurophet AQUA PR Newswire
||
Demonstrates MS Analysis Technology, Recently Secured FDA 510(k) Clearance Introduces ‘Neurophet AQUA AD,’ a Total Solution for Alzheimer’s Disease Treatment Prescription, at the AI Theater SEOUL, South Korea, Dec.... 
Aberdeen Appoints Seasoned Mining Executive Dev Shetty as Executive Chairman and New CEO and Other Corporate UpdatesAberdeen Appoints Seasoned Mining Executive Dev Shetty as Executive Chairman and New CEO and Other Corporate Updates GlobeNewswire
||
TORONTO, Dec. 05, 2024 (GLOBE NEWSWIRE) — ABERDEEN INTERNATIONAL INC. (“Aberdeen” or the “Company”) (TSX: AAB F:A8H, OTC:AABVF) is pleased to announce the appointment of Dev Shetty as Chief... 
Scality and Climb Channel Solutions Partner to Reimagine Distribution for AI and Cyber-resilient Storage SoftwareScality and Climb Channel Solutions Partner to Reimagine Distribution for AI and Cyber-resilient Storage Software GlobeNewswire
||
EATONTOWN, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) — Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB) yesterday announced... 
Churchill Prioritizes TB-01 Nickel Target for Follow-up Exploration at the Taylor Brook Project, Newfoundland & LabradorChurchill Prioritizes TB-01 Nickel Target for Follow-up Exploration at the Taylor Brook Project, Newfoundland & Labrador GlobeNewswire
||
TORONTO, Dec. 05, 2024 (GLOBE NEWSWIRE) — Churchill Resources Inc. (“Churchill” or the “Company”) (TSXV: CRI) is pleased to provide an update on its Taylor Brook nickel project where... 
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid TumorsMonte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors GlobeNewswire
||
Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days... Talen Energy Corporation Announces Launch of $600 Million Term Loan B Financing and Repurchase of Common StockTalen Energy Corporation Announces Launch of $600 Million Term Loan B Financing and Repurchase of Common Stock GlobeNewswire
||
HOUSTON, Dec. 05, 2024 (GLOBE NEWSWIRE) — Talen Energy Corporation (“Talen” or the “Company”) (NASDAQ: TLN) announced today that the Company has launched an incremental Term Loan B credit... 
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder CancerGroundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer GlobeNewswire
||
– 74.5% of patients achieved a complete response at any time – – Median duration of response is greater than 27 months and not reached – – Latest data... 
The M Jewelers Opens Investment Opportunity to Public Through StartEngine CampaignThe M Jewelers Opens Investment Opportunity to Public Through StartEngine Campaign GlobeNewswire
||
The M Jewelers is now live for investments on StartEngine. New York, NY, Dec. 05, 2024 (GLOBE NEWSWIRE) — The M Jewelers, the brand behind Nike and MLB’s most... 
Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBCProtara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC GlobeNewswire
||
TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures100% six-month landmark complete response rate and 80% complete response rate...